# Spire Global, Inc.: financial statements, quarterly

SPIR · NYSE · CIK 1816017 · [Communication](/sectors/communication.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/spir.md) · [Financials](/companies/spir/financials.md) · [Filings](/companies/spir/filings.md) · [Insiders](/companies/spir/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/spir/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [22.1](/filings/0000950170-25-030877.md) | [24.2 d](/filings/0000950170-25-051157.md) | [34.8](/filings/0000950170-25-071394.md) | [25.4](/filings/0001193125-25-262935.md) | [28.6](/filings/0001193125-25-322735.md) | [21.7 d](/filings/0001193125-26-116169.md) | [23.9](/filings/0001193125-26-222710.md) | [19.2](/filings/0001193125-26-347865.md) | [12.7](/filings/0001193125-25-322735.md) | [15.8 d](/filings/0001193125-26-116169.md) | [15.8](/filings/0001193125-26-222710.md) | [18.0](/filings/0001193125-26-347865.md) |
| Cost of revenue | $m | [12.6](/filings/0000950170-25-030877.md) | [17.8 d](/filings/0000950170-25-051157.md) | [25.6](/filings/0000950170-25-071394.md) | [14.5](/filings/0001193125-25-262935.md) | [15.8](/filings/0001193125-25-322735.md) | [14.6 d](/filings/0001193125-26-116169.md) | [15.2](/filings/0001193125-26-222710.md) | [9.8](/filings/0001193125-26-347865.md) | [8.0](/filings/0001193125-25-322735.md) | [9.4 d](/filings/0001193125-26-116169.md) | [9.5](/filings/0001193125-26-222710.md) | [11.9](/filings/0001193125-26-347865.md) |
| Gross profit | $m | [9.5](/filings/0000950170-25-030877.md) | [6.4 d](/filings/0000950170-25-051157.md) | [9.2](/filings/0000950170-25-071394.md) | [10.9](/filings/0001193125-25-262935.md) | [12.7](/filings/0001193125-25-322735.md) | [7.0 d](/filings/0001193125-26-116169.md) | [8.7](/filings/0001193125-26-222710.md) | [9.4](/filings/0001193125-26-347865.md) | [4.6](/filings/0001193125-25-322735.md) | [6.4 d](/filings/0001193125-26-116169.md) | [6.3](/filings/0001193125-26-222710.md) | [6.2](/filings/0001193125-26-347865.md) |
| Research and development | $m | [7.9](/filings/0000950170-25-030877.md) | [4.7 d](/filings/0000950170-25-051157.md) | [6.0](/filings/0000950170-25-071394.md) | [7.5](/filings/0001193125-25-262935.md) | [5.6](/filings/0001193125-25-322735.md) | [10.1 d](/filings/0001193125-26-116169.md) | [8.7](/filings/0001193125-26-222710.md) | [10.2](/filings/0001193125-26-347865.md) | [9.1](/filings/0001193125-25-322735.md) | [8.7 d](/filings/0001193125-26-116169.md) | [8.7](/filings/0001193125-26-222710.md) | [8.2](/filings/0001193125-26-347865.md) |
| Operating income | $m | [(16.8)](/filings/0000950170-25-030877.md) | [(13.1) d](/filings/0000950170-25-051157.md) | [(12.0)](/filings/0000950170-25-071394.md) | [(12.4)](/filings/0001193125-25-262935.md) | [(13.7)](/filings/0001193125-25-322735.md) | [(31.2) d](/filings/0001193125-26-116169.md) | [(28.3)](/filings/0001193125-26-222710.md) | [(23.5)](/filings/0001193125-26-347865.md) | [(21.1)](/filings/0001193125-25-322735.md) | [(23.1) d](/filings/0001193125-26-116169.md) | [(24.6)](/filings/0001193125-26-222710.md) | [(19.9)](/filings/0001193125-26-347865.md) |
| Interest expense | $m | [4.7](/filings/0000950170-23-061167.md) | [5.0 d](/filings/0000950170-25-051157.md) | [5.1](/filings/0000950170-25-071394.md) | [4.8](/filings/0001193125-25-262935.md) | [4.8](/filings/0001193125-25-322735.md) | [5.7 d](/filings/0001193125-26-116169.md) | [5.7](/filings/0001193125-26-222710.md) | [1.7](/filings/0001193125-26-347865.md) | [0.0](/filings/0001193125-25-322735.md) | [0.0 d](/filings/0001193125-26-116169.md) | [0.0](/filings/0001193125-26-222710.md) | [0.0](/filings/0001193125-26-347865.md) |
| Income tax | $m | [(0.0)](/filings/0000950170-25-030877.md) | [(0.6) d](/filings/0000950170-25-051157.md) | [(0.0)](/filings/0000950170-25-071394.md) | [0.1](/filings/0001193125-25-262935.md) | [0.0](/filings/0001193125-25-322735.md) | [0.1 d](/filings/0001193125-26-116169.md) | [(0.0)](/filings/0001193125-26-222710.md) | [1.8](/filings/0001193125-26-347865.md) | [(0.0)](/filings/0001193125-25-322735.md) | [1.8 d](/filings/0001193125-26-116169.md) | [0.1](/filings/0001193125-26-222710.md) | [0.3](/filings/0001193125-26-347865.md) |
| Net income | $m | [(23.3)](/filings/0000950170-25-030877.md) | [(17.2) d](/filings/0000950170-25-051157.md) | [(25.5)](/filings/0000950170-25-071394.md) | [(16.6)](/filings/0001193125-25-262935.md) | [(12.5)](/filings/0001193125-25-322735.md) | [(48.8) d](/filings/0001193125-26-116169.md) | [(23.5)](/filings/0001193125-26-347865.md) | [120](/filings/0001193125-26-347865.md) | [(19.7)](/filings/0001193125-25-322735.md) | [(25.1) d](/filings/0001193125-26-116169.md) | [(25.8)](/filings/0001193125-26-347865.md) | [(20.0)](/filings/0001193125-26-347865.md) |
| Diluted EPS | $ per share | [(1.12)](/filings/0000950170-25-030877.md) | not reported | [(1.17)](/filings/0000950170-25-071394.md) | [(0.68)](/filings/0001193125-25-262935.md) | [(0.50)](/filings/0001193125-25-322735.md) | not reported | [(0.88)](/filings/0001193125-26-222710.md) | [3.72](/filings/0001193125-26-347865.md) | [(0.61)](/filings/0001193125-25-322735.md) | not reported | [(0.78)](/filings/0001193125-26-222710.md) | [(0.52)](/filings/0001193125-26-347865.md) |
| Basic EPS | $ per share | [(1.12)](/filings/0000950170-25-030877.md) | not reported | [(1.17)](/filings/0000950170-25-071394.md) | [(0.68)](/filings/0001193125-25-262935.md) | [(0.50)](/filings/0001193125-25-322735.md) | not reported | [(0.88)](/filings/0001193125-26-222710.md) | [3.80](/filings/0001193125-26-347865.md) | [(0.61)](/filings/0001193125-25-322735.md) | not reported | [(0.78)](/filings/0001193125-26-222710.md) | [(0.52)](/filings/0001193125-26-347865.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [29.9](/filings/0000950170-23-061167.md) | [29.1](/filings/0000950170-25-051157.md) | [51.7](/filings/0000950170-25-030862.md) | [23.5](/filings/0000950170-25-030868.md) | [29.1](/filings/0000950170-25-030877.md) | [19.2](/filings/0001193125-26-116169.md) | [35.9](/filings/0000950170-25-071394.md) | [36.1](/filings/0001193125-25-262935.md) | [20.3](/filings/0001193125-25-322735.md) | [24.8](/filings/0001193125-26-347865.md) | [16.0](/filings/0001193125-26-222710.md) | [38.8](/filings/0001193125-26-347865.md) |
| Current assets | $m | [81.6](/filings/0000950170-23-061167.md) | [72.3](/filings/0000950170-25-051157.md) | [90.2](/filings/0000950170-25-030862.md) | [71.3](/filings/0000950170-25-030868.md) | [58.2](/filings/0000950170-25-030877.md) | [92.2](/filings/0001193125-26-116169.md) | [108](/filings/0000950170-25-071394.md) | [132](/filings/0001193125-25-262935.md) | [113](/filings/0001193125-25-322735.md) | [93.8](/filings/0001193125-26-347865.md) | [64.4](/filings/0001193125-26-222710.md) | [110](/filings/0001193125-26-347865.md) |
| Total assets | $m | [256](/filings/0000950170-23-061167.md) | [239](/filings/0000950170-25-051157.md) | [252](/filings/0000950170-25-030862.md) | [231](/filings/0000950170-25-030868.md) | [224](/filings/0000950170-25-030877.md) | [194](/filings/0001193125-26-116169.md) | [209](/filings/0000950170-25-071394.md) | [240](/filings/0001193125-25-262935.md) | [224](/filings/0001193125-25-322735.md) | [211](/filings/0001193125-26-347865.md) | [183](/filings/0001193125-26-222710.md) | [227](/filings/0001193125-26-347865.md) |
| Current liabilities | $m | [42.8](/filings/0000950170-23-061167.md) | [49.3](/filings/0000950170-25-051157.md) | [41.4](/filings/0000950170-25-030862.md) | [140](/filings/0000950170-25-030868.md) | [144](/filings/0000950170-25-030877.md) | [152](/filings/0001193125-26-116169.md) | [162](/filings/0000950170-25-071394.md) | [54.4](/filings/0001193125-25-262935.md) | [59.4](/filings/0001193125-25-322735.md) | [72.3](/filings/0001193125-26-347865.md) | [68.5](/filings/0001193125-26-222710.md) | [58.7](/filings/0001193125-26-347865.md) |
| Total liabilities | $m | [179](/filings/0000950170-23-061167.md) | [201](/filings/0000950170-25-051157.md) | [200](/filings/0000950170-25-030862.md) | [190](/filings/0000950170-25-030868.md) | [193](/filings/0000950170-25-030877.md) | [205](/filings/0001193125-26-116169.md) | [203](/filings/0000950170-25-071394.md) | [90.3](/filings/0001193125-25-262935.md) | [91.1](/filings/0001193125-25-322735.md) | [98.1](/filings/0001193125-26-347865.md) | [91.7](/filings/0001193125-26-222710.md) | [82.4](/filings/0001193125-26-347865.md) |
| Long-term debt | $m | [118](/filings/0000950170-23-061167.md) | [114](/filings/0000950170-25-051157.md) | [115](/filings/0000950170-25-030862.md) | [4.9](/filings/0000950170-25-030868.md) | [4.9](/filings/0000950170-25-030877.md) | [4.6](/filings/0001193125-26-116169.md) | [0.0](/filings/0000950170-25-071394.md) | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | [0.0](/filings/0000950170-25-051157.md) | not reported | [101](/filings/0000950170-25-030868.md) | [92.2](/filings/0000950170-25-030877.md) | [93.9](/filings/0001193125-26-116169.md) | [100](/filings/0000950170-25-071394.md) | [0.0](/filings/0001193125-25-262935.md) | [0.0](/filings/0001193125-25-322735.md) | [0.0](/filings/0001193125-26-116169.md) | not reported | not reported |
| Shareholders' equity | $m | [50.1](/filings/0000950170-25-030877.md) | [37.8](/filings/0001193125-26-116169.md) | [52.5](/filings/0001193125-25-262935.md) | [40.3](/filings/0001193125-25-322735.md) | [30.8](/filings/0001193125-25-322735.md) | [(11.7)](/filings/0001193125-26-347865.md) | [3.7](/filings/0001193125-26-347865.md) | [149](/filings/0001193125-26-347865.md) | [133](/filings/0001193125-25-322735.md) | [113](/filings/0001193125-26-347865.md) | [91.2](/filings/0001193125-26-347865.md) | [144](/filings/0001193125-26-347865.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(10.8) d](/filings/0000950170-25-030877.md) | [3.1 d](/filings/0000950170-25-051157.md) | [(8.9)](/filings/0000950170-25-071394.md) | [(4.4) d](/filings/0001193125-25-262935.md) | [14.0 d](/filings/0001193125-25-322735.md) | [(19.2) d](/filings/0001193125-26-116169.md) | [(8.4)](/filings/0001193125-26-222710.md) | [(35.1) d](/filings/0001193125-26-347865.md) | [(12.0) d](/filings/0001193125-25-322735.md) | [(4.3) d](/filings/0001193125-26-116169.md) | [(26.2)](/filings/0001193125-26-222710.md) | [(23.4) d](/filings/0001193125-26-347865.md) |
| Capital expenditure | $m | [5.3 d](/filings/0000950170-25-030877.md) | [5.4 d](/filings/0000950170-25-051157.md) | [7.1](/filings/0000950170-25-071394.md) | [5.5 d](/filings/0001193125-25-262935.md) | [8.9 d](/filings/0001193125-25-322735.md) | [5.1 d](/filings/0001193125-26-116169.md) | [8.9](/filings/0001193125-26-222710.md) | [3.6 d](/filings/0001193125-26-347865.md) | [8.4 d](/filings/0001193125-25-322735.md) | [11.9 d](/filings/0001193125-26-116169.md) | [8.0](/filings/0001193125-26-222710.md) | [5.5 d](/filings/0001193125-26-347865.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [17.5](/filings/0000950170-23-061167.md) | [18.1](/filings/0000950170-25-030862.md) | [18.5](/filings/0000950170-25-030868.md) | [20.8](/filings/0000950170-25-030877.md) | [21.8](/filings/0000950170-25-071394.md) | [24.5](/filings/0001193125-25-262935.md) | [24.9](/filings/0001193125-25-322735.md) | [26.8](/filings/0001193125-26-222710.md) | [32.1](/filings/0001193125-26-347865.md) | [32.5](/filings/0001193125-25-322735.md) | [33.3](/filings/0001193125-26-222710.md) | [38.3](/filings/0001193125-26-347865.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.